TherapeuticsMD (TXMD) Receivables - Other (2012 - 2026)

TherapeuticsMD has reported Receivables - Other for 8 years, with the latest figure at $3.2 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other rose 7.18% year-over-year to $3.2 million; the trailing twelve-month figure through Mar 2026 stood at $3.2 million (up 7.18% YoY), and the FY2025 full-year result was $3.5 million, down 81.99% from the prior year.
• Receivables - Other for Q1 2026 stood at $3.2 million, down from $3.5 million in the prior quarter.
• The five-year high for Receivables - Other was $21.6 million in Q4 2023, with the low at $2.9 million in Q2 2024.
• Historically, Receivables - Other has averaged $6.8 million across 4 years, with a median of $3.4 million in 2024.
• The largest YoY upside for Receivables - Other was 28.71% in 2025 against a maximum downside of 81.99% in 2025.
• TherapeuticsMD's Receivables - Other stood at $21.6 million in 2023, then retreated by 9.28% to $19.6 million in 2024, then sank by 81.99% to $3.5 million in 2025, then dropped by 8.91% to $3.2 million in 2026.
• The last three Receivables - Other figures came in at $3.2 million (Q1 2026), $3.5 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.